Publications by authors named "J M Arbelo"
Article Synopsis
- Advanced Parkinson's Disease (APD) is characterized by severe symptoms and a poor response to standard treatments, but its prevalence has not been well-studied historically.
- The study aimed to assess the prevalence of APD among patients with idiopathic Parkinson's disease in Spanish hospitals, while also examining the broader characteristics of PD patients.
- Findings revealed that 38.2% of patients had APD, with relevant statistics on demographic factors, co-morbidities, quality of life, and treatment options available for advanced stages of the disease.
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson's Disease (APD) patients QoL.
View Article and Find Full Text PDFSpanish expert consensus on the use of safinamide in Parkinson's disease.
Neurologia (Engl Ed)
November 2021
Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of safinamide have been conducted to date. This study provides clinical management guidelines for safinamide based on the opinion of a group of experts in movement disorders.
View Article and Find Full Text PDFWe would like to submit the following erratum to our recently published paper [...
View Article and Find Full Text PDFSafinamide is an approved drug for the treatment of fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice.
View Article and Find Full Text PDF